Maria E. Arango

2.6k total citations · 2 hit papers
20 papers, 2.1k citations indexed

About

Maria E. Arango is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Maria E. Arango has authored 20 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Oncology and 7 papers in Cell Biology. Recurrent topics in Maria E. Arango's work include Glycosylation and Glycoproteins Research (8 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Proteoglycans and glycosaminoglycans research (4 papers). Maria E. Arango is often cited by papers focused on Glycosylation and Glycoproteins Research (8 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Proteoglycans and glycosaminoglycans research (4 papers). Maria E. Arango collaborates with scholars based in United States, United Kingdom and Australia. Maria E. Arango's co-authors include James G. Christensen, Gerrit Los, Kermit L. Carraway, Joseph H. Lee, Qiuhua Li, Helen Y. Zou, Shinji Yamazaki, Scott R. McDonnell, Gordon Alton and Barbara Mroczkowski and has published in prestigious journals such as Cancer Research, Oncogene and Biochemical Journal.

In The Last Decade

Maria E. Arango

19 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

2007 593 citations Helen Y. Zou, Qiuhua Li et al. Cancer Research profile →
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

2007 513 citations James G. Christensen, Helen Y. Zou et al. Molecular Cancer Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria E. Arango United States	15	1.2k	1.1k	695	261	249	20	2.1k
Cheng‐long Huang Japan	26	1.3k 1.1×	973 0.9×	673 1.0×	129 0.5×	129 0.5×	68	2.3k
Silvia Benvenuti Italy	20	969 0.8×	1.6k 1.5×	923 1.3×	147 0.6×	586 2.4×	40	2.6k
Todd Hembrough United States	25	942 0.8×	880 0.8×	524 0.8×	149 0.6×	293 1.2×	71	2.3k
Lon Smith United States	17	1.1k 0.9×	1.8k 1.7×	429 0.6×	183 0.7×	165 0.7×	35	2.5k
Amrita Desai United States	19	657 0.5×	1.3k 1.2×	1.1k 1.6×	134 0.5×	274 1.1×	36	2.3k
Rosa Caputo Italy	20	1.0k 0.8×	1.3k 1.3×	906 1.3×	218 0.8×	163 0.7×	21	2.3k
Soji Kakiuchi Japan	21	998 0.8×	850 0.8×	910 1.3×	86 0.3×	116 0.5×	41	1.9k
Élodie Vauléon France	24	522 0.4×	596 0.6×	414 0.6×	132 0.5×	151 0.6×	60	1.8k
Muralidhar Beeram United States	27	1.3k 1.1×	1.7k 1.6×	835 1.2×	616 2.4×	243 1.0×	89	3.0k
Marie Prewett United States	18	1.4k 1.2×	1.7k 1.6×	816 1.2×	661 2.5×	175 0.7×	34	2.9k

Countries citing papers authored by Maria E. Arango

Since Specialization

Citations

This map shows the geographic impact of Maria E. Arango's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria E. Arango with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria E. Arango more than expected).

Fields of papers citing papers by Maria E. Arango

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria E. Arango. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria E. Arango. The network helps show where Maria E. Arango may publish in the future.

Co-authorship network of co-authors of Maria E. Arango

This figure shows the co-authorship network connecting the top 25 collaborators of Maria E. Arango. A scholar is included among the top collaborators of Maria E. Arango based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria E. Arango. Maria E. Arango is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arango, Maria E. & Carl I. Schulman. (2023). 753 Aquatic Therapy Improves Functional Outcomes in a Pediatric Burn Patient. Journal of Burn Care & Research. 44(Supplement_2). S159–S159.

Friedl, W, et al.. (2021). Using Behavior Science to Maximize Human Performance. 2 indexed citations

Zou, Helen Y., Qiuhua Li, Joseph H. Lee, et al.. (2012). Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor. Molecular Cancer Therapeutics. 11(4). 1036–1047. 57 indexed citations

Cullinane, Carleen, Donna S. Dorow, Susan Jackson, et al.. (2011). Differential ¹⁸F-FDG and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models. Journal of Nuclear Medicine. 52(8). 1261–1267. 29 indexed citations

Zhang, Cathy C., Zhengming Yan, Qin Zhang, et al.. (2010). PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity. Clinical Cancer Research. 16(21). 5177–5188. 58 indexed citations

Zhang, Cathy, Zhengming Yan, Cory L. Painter, et al.. (2009). PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts. Clinical Cancer Research. 15(14). 4630–4640. 45 indexed citations

Blasina, Alessandra, Jill Hallin, Enhong Chen, et al.. (2008). Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Molecular Cancer Therapeutics. 7(8). 2394–2404. 171 indexed citations

Zhang, Cathy, Zhengming Yan, Maria E. Arango, Cory L. Painter, & Kenna Anderes. (2008). Advancing Bioluminescence Imaging Technology for the Evaluation of Anticancer Agents in the MDA-MB-435-HAL-Luc Mammary Fat Pad and Subrenal Capsule Tumor Models. Clinical Cancer Research. 15(1). 238–246. 32 indexed citations

Zhang, Cathy, Karen Lundgren, Zhengming Yan, et al.. (2008). Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy. Molecular Cancer Therapeutics. 7(4). 818–828. 8 indexed citations

10.

Zou, Helen Y., Qiuhua Li, Joseph H. Lee, et al.. (2007). An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms. Cancer Research. 67(9). 4408–4417. 593 indexed citations breakdown →

11.

Christensen, James G., Helen Y. Zou, Maria E. Arango, et al.. (2007). Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular Cancer Therapeutics. 6(12). 3314–3322. 513 indexed citations breakdown →

12.

Zhang, Cathy C., Susan E. Kephart, Indrawan McAlpine, et al.. (2005). AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity. Cancer Research. 65. 1045–1045. 8 indexed citations

13.

Carraway, Kermit L., Aymee Perez, Scott Jepson, et al.. (2002). Muc4/sialomucin complex, the intramembrane Er6B2 ligand, in cancer and epithelia: To protect and to survive. Progress in nucleic acid research and molecular biology. 71. 149–185. 94 indexed citations

14.

Price‐Schiavi, Shari A., Scott Jepson, Peter Li, et al.. (2002). Rat Muc4 (sialomucin complex) reduces binding of anti‐ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. International Journal of Cancer. 99(6). 783–791. 157 indexed citations

15.

Arango, Maria E., et al.. (2002). An ErbB2-Muc4 complex in rat ocular surface epithelia. Current Eye Research. 24(5). 397–402. 18 indexed citations

16.

Jepson, Scott, Masanobu Komatsu, Bushra Haq, et al.. (2002). Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip, but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways. Oncogene. 21(49). 7524–7532. 116 indexed citations

17.

Komatsu, Masanobu, Maria E. Arango, & Kermit L. Carraway. (2002). Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis. Biochemical Journal. 368(1). 41–48. 41 indexed citations

18.

Arango, Maria E., Peter Li, Masanobu Komatsu, et al.. (2001). Production and localization of Muc4/sialomucin complex and its receptor tyrosine kinase ErbB2 in the rat lacrimal gland.. PubMed. 42(12). 2749–56. 42 indexed citations

19.

Komatsu, Masanobu, Scott Jepson, Maria E. Arango, Coralie A. Carothers Carraway, & Kermit L. Carraway. (2001). Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene. 20(4). 461–470. 106 indexed citations

20.

Li, Peter, et al.. (2001). Expression and localization of immunoreactive-sialomucin complex (Muc4) in salivary glands. Tissue and Cell. 33(1). 111–118. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact